Leaflet REFACTO AF 2000UI powder+solution for injection
Indicated for: bleeding; coagulation disorders
Route of administration: injectable
Substance: moroctocog alfa (anticoagulant)
ATC: B02BD02 (Blood and blood forming organs | Vitamin k and other hemostatics | Blood coagulation factors)
Dose adjustment may be needed in kidney disease.
This medicine may have important interactions with other medicines.
This medicine is subject to additional monitoring.
Use during breastfeeding only on medical advice.
Use during pregnancy only on medical advice.
This medicine may increase the risk of bleeding.
Moroctocog alfa is a medication used for the treatment and prevention of bleeding episodes in patients with hemophilia A. It is a recombinant form of coagulation factor VIII, essential for blood clotting.
The medication is administered intravenously and is indicated for both the treatment of acute bleeding episodes and long-term prophylaxis. It is effective in reducing the frequency of bleeding episodes and preventing associated complications.
Side effects may include headache, fever, injection site reactions, or, in rare cases, severe allergic reactions. It is important to monitor factor VIII levels and follow your doctor's instructions.
Consult your doctor to discuss the benefits and risks of treatment with Moroctocog alfa. Regular monitoring is essential to ensure the therapy's effectiveness.
General data about REFACTO AF 2000UI
- Substance: moroctocog alfa
- Date of last drug list: 01-06-2024
- Commercial code: W61062001
- Concentration: 2000UI
- Pharmaceutical form: powder+solution for injection
- Quantity: 1
- Product type: original
- Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).
Pharmaceutical forms available for moroctocog alfa
Concentrations available for moroctocog alfa
- 1000UI
- 2000UI
- 250UI
- 500UI